The FDA has continued to issue safety alerts and investigate events surrounding the injectable blood thinner heparin (FDA News, April 2008) and its “clear link” to 81 deaths in U.S. patients who received doses of the drug.
Special Protocol Assessment (SPA) approval has been given to Ark Therapeutics Group plc of London for a phase III pivotal trial of Trinam, a novel gene-based medicine to prevent blood vessel blockage in kidney dialysis patients who have undergone vascular access graft surgery.
Calypso Medical of Seattle announced that the FDA has cleared a new indication for use of implantable Beacon electromagnetic transponders with its external-beam radiation therapy (EBRT), known as GPS for the Body, to continuously track the position of targeted tissue during treatment of prostatectomy patients.
Limits on awards for noneconomic damages are unconstitutional, a Georgia judge has ruled.
Patients who want to sue a doctor in Tennessee will first have to get a medical expert to certify that their charges have merit under a new state law.
A negligence lawyer’s gaffe has a New York urologist breathing easier these days. He’s off the hook in a malpractice suit while the attorney is being sued.
A San Francisco man has won a $5.1 million malpractice settlement from the city after the staff at a municipal hospital botched his treatment for acute renal failure.
Evaluating how predialysis patients rise from a chair may provide a simple way to identify those who need help with muscle training and functional exercise, according to researchers in Sweden and Norway.
Six months of mycophenolate mofetil (MMF) treatment is as effective in the short term as conventional therapy for primary treatment of membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), a pilot study in India found.
Patient weight changes after renal transplantation may be a marker for poor survival, data suggest.
